相关实验视频
Updated: Jul 13, 2025

15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
9.6K
简氏激酶抑制剂是对肌缩性侧面硬化症的潜在治疗方法
Peter J Richardson1, Daniel P Smith2, Alex de Giorgio2
1BenevolentAI, 4-8 Maple Street, London, W1T 5HD, UK. peter.richardson@benevolent.ai.
Translational neurodegeneration
|October 12, 2023
概括
简氏激酶 (JAK) /信号转换器和转录激活器 (STAT) 信号传输与肌肉增生侧面硬化症 (ALS) 有关. 使用Jakinibs抑制这种途径,就像巴里西丁尼布一样,可能为ALS治疗提供了一个新的治疗策略.
科学领域:
- 神经退行性疾病的神经退行性疾病
- 神经炎症是一种神经炎症.
- 细胞信号通道是细胞信号通道.
背景情况:
- 肌缩侧面硬化 (ALS) 是一种复杂,多因素的神经退行性疾病,治疗选择有限.
- 多因素性疾病的有效治疗通常需要针对多种病理过程.
- 简氏激酶 (JAK) /信号转换器和转录激活器 (STAT) 信号传输是涉及各种细胞功能和疾病的关键途径.
研究的目的:
- 审查JAK/STAT信号在ALS发病过程中的作用.
- 确认JAK/STAT信号与ALS疾病核心机制之间的关联.
- 评估JAK抑制剂 (Jakinibs) 作为ALS治疗策略的潜力.
主要方法:
- 对ALS中JAK/STAT通路的文献综述和分析.
- 使用BenevolentAI的知识图来识别JAK/STAT信号与ALS病理之间的联系.
- 评估Jakinibs在临床前模型中的潜在疗效及其药理动力学特性.
主要成果:
- 证实了JAK/STAT信号通路与基本的ALS疾病过程有关.
- 抑制JAK/STAT信号传递有可能缓解多种细胞类型的ALS病理生理学,包括神经元,神经质,肌肉纤维和血液细胞.
- 巴里西提尼布是一种JAK抑制剂,对中枢神经系统的透和免疫调节具有有利的特性,使其成为一个有前途的候选者.
结论:
- 抑制JAK/STAT通路代表了ALS的可行的治疗策略.
- 由于其特性,巴里西提尼布是ALS临床研究的强有力的候选者.
- 建议进行进一步的临床试验,以评估巴里西提尼布在治疗ALS方面的疗效.
相关概念视频
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Parkinson's Disease: Treatment
283
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
283
Satellite Stem Cells and Muscular Dystrophy
2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Alzheimer's Disease: Treatment
211
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
211
cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K

